Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.71 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | THPO | P40225 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | APEX1 | P27695 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL163444 | 1.00 | CYP3A4 (0.71) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| Hydrochloric Acid SCHEMBL28331180 | 0.98 | CYP3A4 (0.69) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL9082370 | 0.94 | CYP3A4 (0.63) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL9083164 | 0.94 | CYP3A4 (0.63) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL15911724 | 0.94 | CYP3A4 (0.63) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL28328192 | 0.94 | CYP3A4 (0.67) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL1673289 | 0.93 | CYP3A4 (0.61) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| Sulfuric Acid SCHEMBL9797625 | 0.93 | CYP3A4 (0.61) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL3457999 | 0.93 | CYP3A4 (0.61) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL5221763 | 0.92 | CYP3A4 (0.65) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3856167-A1 | USE OF HISTIDINE, GLYCINE AND OTHER AMINOACIDS FOR PREVENTING INSULIN RESISTANCE AND/OR DIABETES | Société des Produits Nestlé S.A. (CH) | 2021-08-04 | — | — | EP | disclosed |
| WO-2020064692-A1 | USE OF HISTIDINE, GLYCINE AND OTHER AMINOACIDS FOR PREVENTING INSULIN RESISTANCE AND/OR DIABETES | Société des Produits Nestlé S.A. (CH) | 2020-04-02 | — | — | WO | disclosed |
| US-8785381-B2 | Oral GLP-1 formulations | EMISPHERE TECHNOLOGIES, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| WO-2011144358-A1 | HISTIDINE-CONTAINING SOLUTION FOR TRANSFECTION AND/OR INJECTION OF NUCLEIC ACIDS AND USES THEREOF | CUREVAC GMBH (DE) | 2011-11-24 | — | — | WO | disclosed |
| EP-2296693-A1 | COMPOSITIONS FOR ENHANCING THE ANTIBACTERIAL ACTIVITY OF MYELOPEROXIDASE AND METHODS OF USE THEREOF | Exoxemis, Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| US-20100016229-A1 | Oral GLP-1 Formulations | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2010-01-21 | — | — | US | disclosed |
| WO-2009137697-A1 | COMPOSITIONS FOR ENHANCING THE ANTIBACTERIAL ACTIVITY OF MYELOPEROXIDASE AND METHODS OF USE THEREOF | EXOXEMIS, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016229-A1 | Oral GLP-1 Formulations | GLP1R, GIPR, GCGR | CYP3A4 1114/4885SLC7A5 1315/4885HRH4 1077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.